Cytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest Update
Cytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest Update
Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 3,970,000 shares, an increase of 9.7% from the December 31st total of 3,620,000 shares. Based on an average trading volume of 598,100 shares, the days-to-cover ratio is currently 6.6 days. Currently, 4.3% of the company's shares are short sold.
賽特克生物科學公司(納斯達克代碼：CTKB-GET Rating)在一月份見證了空頭股數的大幅增長。截至1月15日，空頭股數共有397萬股，比12月31日的362萬股增加了9.7%。以598,100股的平均成交量計算，目前天數與回補比率為6.6天。目前，該公司4.3%的股票被賣空。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Separately, Piper Sandler increased their target price on Cytek Biosciences from $16.00 to $18.00 in a research note on Monday, November 14th.
另外，派珀·桑德勒在11月14日週一的一份研究報告中將Cytek Biosciences的目標價從16.00美元上調至18.00美元。
Insider Activity
內幕活動
In other news, Director Jack Ball sold 16,000 shares of the company's stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $14.69, for a total value of $235,040.00. Following the completion of the sale, the director now directly owns 3,000 shares of the company's stock, valued at approximately $44,070. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Patrik Jeanmonod sold 3,500 shares of the company's stock in a transaction dated Tuesday, January 24th. The stock was sold at an average price of $11.05, for a total value of $38,675.00. Following the completion of the sale, the chief financial officer now directly owns 76,132 shares of the company's stock, valued at approximately $841,258.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jack Ball sold 16,000 shares of the stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $14.69, for a total value of $235,040.00. Following the sale, the director now directly owns 3,000 shares of the company's stock, valued at $44,070. The disclosure for this sale can be found here. Insiders sold a total of 146,500 shares of company stock valued at $1,824,960 in the last ninety days. 15.90% of the stock is owned by insiders.
在其他新聞方面，董事傑克球在一筆日期為11月14日星期一的交易中出售了16,000股該公司股票。該股以14.69美元的平均價格出售，總價值為235,040.00美元。出售完成後，董事現在直接持有該公司3000股股票，價值約44,070美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過此超鏈接。在其他新聞方面，首席財務官Patrik Jeanmonod在1月24日星期二的交易中出售了3500股公司股票。這隻股票的平均售價為11.05美元，總價值為38,675.00美元。出售完成後，首席財務官現在直接擁有76,132股公司股票，價值約841,258.60美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過此超鏈接。此外，在11月14日(星期一)的一次交易中，董事傑克球出售了16,000股該股。該股以14.69美元的平均價格出售，總價值為235,040.00美元。交易完成後，董事現在直接持有該公司3000股股票，價值44,070美元。關於這次銷售的披露可以找到這裏。在過去的90天裏，內部人士總共拋售了146,500股公司股票，價值1,824,960美元。15.90%的股份由內部人士持有。
Institutional Investors Weigh In On Cytek Biosciences
機構投資者看好賽特克生物科學公司
Cytek Biosciences Stock Performance
賽特克生物科學公司股票表現
NASDAQ CTKB traded up $0.43 during trading hours on Tuesday, reaching $12.14. 286,762 shares of the company's stock were exchanged, compared to its average volume of 706,353. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -1,194.00 and a beta of 0.06. Cytek Biosciences has a one year low of $7.38 and a one year high of $16.05. The company's 50-day moving average is $11.39 and its two-hundred day moving average is $12.99.
在週二的交易時段，新浪納斯達克的股價上漲了0.43美元，達到12.14美元。該公司股票成交量為286,762股，而其平均成交量為706,353股。該公司市值為16.4億美元，市盈率為-1194.00，貝塔係數為0.06。Cytek Biosciences的一年低點為7.38美元，一年高位為16.05美元。該公司50日移動均線切入位在11.39美元，200日移動均線切入位在12.99美元。
Cytek Biosciences (NASDAQ:CTKB – Get Rating) last issued its quarterly earnings results on Wednesday, November 9th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.01). The business had revenue of $40.48 million for the quarter, compared to the consensus estimate of $43.36 million. Cytek Biosciences had a positive return on equity of 0.94% and a negative net margin of 0.47%. Research analysts predict that Cytek Biosciences will post 0.04 earnings per share for the current fiscal year.
賽特克生物科學公司(納斯達克代碼：CTKB-GET Rating)最近一次發佈季度收益報告是在11月9日星期三。該公司公佈本季度每股收益為0.01美元，低於普遍預期的0.02美元(0.01美元)。該業務本季度的收入為4,048萬美元，而普遍預期為4,336萬美元。Cytek Biosciences的股本回報率為正0.94%，淨利潤率為負0.47%。研究分析師預測，Cytek Biosciences本財年的每股收益將為0.04美元。
About Cytek Biosciences
關於賽特克生物科學公司
(Get Rating)
(獲取評級)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
Cytek Biosciences，Inc.是一家細胞分析解決方案公司，提供細胞分析工具，促進生物醫學研究和臨牀應用的科學進步。它提供極光和北極光系統，這是一種光譜流動細胞儀，通過利用來自多個激光的熒光信號來區分單個細胞上的熒光標記來提供細胞分析；以及極光細胞分選系統，它利用全光譜圖譜技術進一步拓寬了細胞分析的潛在應用。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
- 免費獲取StockNews.com關於Cytek生物科學的研究報告(CTKB)
- Verizon，Charge在過去的一個月裏趨勢更高：他們現在購買嗎？
- 股利之王Sysco：逢低買入
- 天才集團股票1600%的漲幅合理嗎？
- 在進一步審查後，投資者喜歡埃克森美孚的收益
- 卡特彼勒會挖出另一個收購機會嗎？
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Cytek生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cytek Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。